Navigation Links
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Date:11/7/2007

tion and other global regulatory agencies and incorporates the most current clinical trial standards and prevailing protocol design for smoking cessation studies. The trial's primary endpoint is the rate of carbon monoxide (CO)-confirmed, continuous abstinence from smoking during weeks 19-26 after first vaccination. In May 2007, Nabi announced this trial's six-month data, which showed that a statistically significant number of patients with in the high anti-nicotine antibody responder group met the trial's primary endpoint of eight weeks of continuous abstinence between weeks 19-26.

About NicVAX(R)

NicVAX(R) is an innovative and proprietary investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX(R) is designed to stimulate the immune system to produce antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier. Therefore, NicVAX(R) blocks nicotine from reaching its receptors in the brain and prevents the highly-addictive pleasure sensation experienced by smokers and users of nicotine products. Pre-clinical and previous clinical data, as well as the study reported here, show that NicVAX(R)'s ability to block nicotine from reaching the brain could help people quit smoking. Because the body's immune system can be boosted to produce long-lasting antibodies, Nabi believes NicVAX(R) also could be effective in preventing smoking relapse. Relapse is a significant challenge facing smokers and, with currently-available smoking cessation therapies, relapse rates can be as high as 90% in the first year after a smoker quits.

NicVAX(R) Development Progress to Date

In September 2005, Nabi announced that it received a $4.1 million grant from the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health. NIDA has also funded, in part, the costs for toxicology testing and earlier clinical trials in the U.S. a
'/>"/>

SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- Today the National Safety Council released a ... effects of pain medications , debunking ... Oxycontin, are safer options than over-the-counter pain relievers. ... on heroin and cocaine combined," said Deborah A.P. ... medications are marketed as the Cadillac option for treating ...
(Date:2/26/2015)... 2015  Mobility Ventures LLC, an AM General Company, ... America (NYSE: BAC ) that will make ... the revolutionary MV-1 - - the world,s first and ... to provide safe and comfortable transportation for all passengers ... to purchase a new MV-1 vehicle at the over ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015 Legislation ... includes a pharmacy provision to help prevent inappropriate prescriptions ... The Protecting the Integrity of Medicare Act (PIMA) ... Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... the prescription drug abuse epidemic and implement the right ...
Breaking Medicine Technology:National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2
... 26, 2011 Reportlinker.com announces that ... available in its catalogue: ... - Forecast to Become The World,s ... http://www.reportlinker.com/p0629405/Emerging-Pharmaceutical-Market-in-China---Forecast-to-Become-The-World,s-Third-Largest-Pharmaceutical-Market-By-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ...
... 2011 PharmaVentures, the experts ... definitive analysis on the dealmaking and financial performance of ... The first release of this monthly report on all ... overtaken GlaxoSmithKline and are now placed second only to ...
Cached Medicine Technology:Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 2Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 3Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 4Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 5Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 6Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 7Pfizer Overtakes GSK but Trails Roche in PharmaDeals' Corp-METRx Analysis of Deal Activity 2Pfizer Overtakes GSK but Trails Roche in PharmaDeals' Corp-METRx Analysis of Deal Activity 3
(Date:3/1/2015)... Michigan (PRWEB) March 01, 2015 Women’s ... to treat Overactive Bladder (OAB) symptoms, such as a strong ... when another type of medication (anticholinergic) does not work well ... treatment option that takes another approach to targeting the source ... works on the nerves and bladder muscle, blocking the signals ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Researchers say ... that so many sheet metal workers contract malignant mesothelioma. ... new report on its website. Click here to ... for Construction Research and Training monitored 17,345 sheet metal ... disproportionate number of them died of mesothelioma or ...
(Date:3/1/2015)... The number of transvaginal mesh lawsuits ( ... weeks in two New Jersey litigations where attorneys at ... announces. , A Case List updated on February ... proceeding established for products manufactured by Johnson & Johnson's ... when 90 fewer cases had been centralized. Additionally, 1,700 ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... technology expert, conducted the review and shared with viewers how ... to Home Distillation of Alcohol, it's understood that oak is ... cool product that’ll help anyone achieve a barrel aged alcohol ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... (Nasdaq: ANSV ) today announced that that John ... the following events in,November: Rodman & Renshaw 9th ... p.m. ET Presentation: http://www.wsw.com/webcast/rrshq12/ansv , 19th ... 4:30 p.m. ET Presentation: http://www.piperjaffray.com/conferences , ...
... Near-term Pipeline of Products Designed to Deter ... Common Methods of ... ,King Pharmaceuticals, Inc. (NYSE: KG ) and Acura Pharmaceuticals, ... entered into,a License, Development and Commercialization Agreement (the "Agreement"),for the ...
... New business awards a record $175 million; net book-to-bill of 1.7:1, - Total business ... margin of 14.2% (GAAP) and 15.3% (proforma) ... revenues of $100.1 million, up 33% over third quarter ... ...
... StemCor Systems, Inc., a,medical device company developing ... it has received 510(k) clearance from,the U.S. ... its MarrowMiner(TM),for the harvest of bone marrow. ... clearance of StemCor,s MarrowMiner is a major,accomplishment ...
... Oct. 30 Barack Obama today,stepped ahead of all ... areas of foreign policy, the effort to eradicate extreme ... area, he pledged to,increase spending on global HIV/AIDS to ... time increasing overall foreign assistance spending to,$50 billion annually. ...
... $45 Million Reflecting 79% Growth Over Prior Year Quarter; ... Guidance and Reaffirms 2008 Guidance, COEUR D,ALENE, Idaho, ... ), the leading provider of radiology,solutions to radiology groups ... third quarter ended September 30, 2007. Revenue,grew 79% year-over-year ...
Cached Medicine News:Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 3Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 4Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 5Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 3Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 4Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 5Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 7Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 8Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 9Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 2Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 3Health News:Obama Pledges Major Expansion of AIDS and Global Poverty Programs 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16
0.5 mm short 120 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
1.0 mm long 120 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
0.5 mm angled tip. Round knurled handle with dull finish. Tip angle: 130 degrees....
Angled for easy insertion into side port incision for manipulation of nucleus. Flat, paddle like tip for placement in groove to crack the nucleus for emulsification....
Medicine Products: